Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064093 | 0.88 | MAPK14 (0.38) | KDRRIPK1MAPK14FLT1BRAF | |
| SCHEMBL5067470 | 0.87 | KDR (0.44) | KDR | |
| SCHEMBL27866380 | 0.83 | BRAF (0.51) | KDRRIPK1BRAF | |
| SCHEMBL3658869 | 0.82 | KDR (0.44) | KDRRIPK1FLT1BRAF | |
| SCHEMBL3663374 | 0.81 | MAPK14 (0.54) | KDRMAPK14BRAF | |
| SCHEMBL3806761 | 0.81 | MAPK14 (0.53) | KDRMAPK14BRAF | |
| SCHEMBL5068791 | 0.79 | KDR (0.41) | KDRBRAF | |
| SCHEMBL3796562 | 0.79 | KDR (0.41) | KDRBRAF | |
| SCHEMBL3812715 | 0.75 | KDR (0.41) | KDR | |
| SCHEMBL2922344 | 0.74 | BRAF (0.47) | KDRRIPK1MAPK14FLT1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | KDR 263/4885RIPK1 727/4885MAPK14 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.